Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens.
about
Treatment of juvenile idiopathic arthritis: a revolution in care2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aGlobal tests of P-values for multifactor dimensionality reduction models in selection of optimal number of target genes.Identifying genomic and developmental causes of adverse drug reactions in children.Nutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis.Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationLow-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.Understanding treatment decision making in juvenile idiopathic arthritis: a qualitative assessment.The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response.The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.Folate usage in MTX-treated juvenile idiopathic arthritis (JIA) patients is inconsistent and highly variable.
P2860
Q26849497-C5976686-FDDB-483A-8E33-FD2B0A1AAEAEQ33613293-E7408B15-403F-4990-8718-39CE176330F2Q34276551-E91F727D-33B6-4645-8977-E23A8ED9CAB7Q34603032-A209D4F2-1F98-4A0B-B429-14733F85B6C6Q34904542-4EE4D451-0CD9-436A-A49C-DE998B579C35Q35223383-3ABE1198-2DC8-4B93-9891-6CD29AAE3A88Q35640471-74991437-E187-491B-AF02-CCCDEE28B59FQ36202845-A6EA2682-D584-4155-B11D-6CE056C2642EQ37006464-91F3F716-79D8-4EAE-9788-F069694459D1Q37193206-F3808115-F9EE-49D6-83B0-50A56525FC9DQ37361905-C8C96618-A414-422A-B919-D2A49641A4E8Q37800874-8EC58817-353B-4CCB-8CEB-F5F53418BCB3Q38672339-6609FF47-0057-498B-80DF-F6EAF20EFD96Q44763585-60ED5B50-0EF0-42DC-B2F1-41D7CC51DC13
P2860
Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@ast
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@en
type
label
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@ast
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@en
prefLabel
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@ast
Effectiveness and toxicity of ...... of 2 initial dosing regimens.
@en
P2093
P2860
P356
P1476
Effectiveness and toxicity of ...... n of 2 initial dosing regimens
@en
P2093
Carlos D Rosé
David D Sherry
Ebbing Lautenbach
Mara L Becker
Warren B Bilker
P2860
P304
P356
10.3899/JRHEUM.090826
P407
P577
2010-03-01T00:00:00Z